NiKem Research Srl and Dualsystems Biotech AG Announce a Strategic Alliance
The ever increasing complexity and expense of drug discovery requires an excellent understanding of molecular targets and mechanism of action in disease early in the research phase to match high quality compound optimisation. Dualsystems offers a proprietary suite of technologies for drug and target profiling from a client’s phenotypic assays. Based on its advanced platforms to discover protein interactions, mechanism of action and target network, information is generated at an early stage of hit-to-lead, lead optimisation or candidate selection. These skills are complemented by the synthetic and medicinal chemistry expertise, the ADMET & DMPK and early toxicology services that NiKem has been providing to its clients over the last 10 years. The combined skills that Dualsystems and NiKem can now offer via a single point of contact make for a highly efficient drug discovery engine. All generated intellectual property is assigned to the client.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.